OCTIMET Oncology is a clinical-stage oncology biotechnology company developing highly selective MET kinase inhibitors licensed from Janssen Pharmaceutica
OCTIMET Oncology is a clinical-stage oncology biotechnology company developing highly selective MET kinase inhibitors licensed from Janssen Pharmaceutica. Its development strategy uses biomarker-based patient selection and pharmacodynamic biomarkers to differentiate treatments and guide clinical development.